{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:40:32Z","timestamp":1790534432651,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,12,28]],"date-time":"2011-12-28T00:00:00Z","timestamp":1325030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00432-011-1123-9","type":"journal-article","created":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T05:48:54Z","timestamp":1324964934000},"page":"545-554","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer"],"prefix":"10.1007","volume":"138","author":[{"given":"Boyka","family":"Markova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia S.","family":"H\u00e4hnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Herbertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Breitenbuecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,28]]},"reference":[{"issue":"20","key":"1123_CR1","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2009.25.4011","volume":"28","author":"RH Alvarez","year":"2010","unstructured":"Alvarez RH, Valero V, Hortobagyi GN (2010) Emerging targeted therapies for breast cancer. J Clin Oncol 28(20):3366\u20133379","journal-title":"J Clin Oncol"},{"issue":"10","key":"1123_CR2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","volume":"34","author":"X An","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS (2010) BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res 34(10):1255\u20131268","journal-title":"Leuk Res"},{"issue":"3","key":"1123_CR3","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","volume":"408","author":"J Bain","year":"2007","unstructured":"Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408(3):297\u2013315","journal-title":"Biochem J"},{"issue":"16","key":"1123_CR4","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1200\/JCO.2008.18.8391","volume":"27","author":"J Baselga","year":"2009","unstructured":"Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS (2009) Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27(16):2630\u20132637","journal-title":"J Clin Oncol"},{"issue":"10","key":"1123_CR5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1097\/JTO.0b013e3181874936","volume":"3","author":"G Bepler","year":"2008","unstructured":"Bepler G, Sommers KE, Cantor A, Li X, Sharma A, Williams C, Chiappori A, Haura E, Antonia S, Tanvetyanon T, Simon G, Obasaju C, Robinson LA (2008) Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer. J Thorac Oncol 3(10):1112\u20131118","journal-title":"J Thorac Oncol"},{"issue":"7","key":"1123_CR6","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1002\/cncr.22208","volume":"107","author":"P Ceppi","year":"2006","unstructured":"Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, Lo Iacono M, Cappia S, Papotti M, Scagliotti GV (2006) Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107(7):1589\u20131596","journal-title":"Cancer"},{"key":"1123_CR7","first-page":"61","volume-title":"Synergism and antagonism in chemotherapy","author":"TC Chou","year":"1991","unstructured":"Chou TC (1991) The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou TCaR DC (ed) Synergism and antagonism in chemotherapy. Academic Press, San Diego, pp 61\u2013102"},{"key":"1123_CR8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"1123_CR9","first-page":"91","volume":"4","author":"C Coppin","year":"2010","unstructured":"Coppin C (2010) Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and\/or sorafenib. Biologics 4:91\u2013101","journal-title":"Biologics"},{"issue":"Pt 1","key":"1123_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/0264-6021:3510095","volume":"351","author":"SP Davies","year":"2000","unstructured":"Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351(Pt 1):95\u2013105","journal-title":"Biochem J"},{"issue":"5","key":"1123_CR11","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/hupa.2002.124122","volume":"33","author":"RP Dematteo","year":"2002","unstructured":"Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33(5):466\u2013477","journal-title":"Hum Pathol"},{"issue":"5","key":"1123_CR12","first-page":"476","volume":"4","author":"Y Dobashi","year":"2011","unstructured":"Dobashi Y, Watanabe Y, Miwa C, Suzuki S, Koyama S (2011) Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 4(5):476\u2013495","journal-title":"Int J Clin Exp Pathol"},{"issue":"56","key":"1123_CR13","doi-asserted-by":"crossref","first-page":"8541","DOI":"10.1038\/sj.onc.1206081","volume":"21","author":"BJ Druker","year":"2002","unstructured":"Druker BJ (2002) Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21(56):8541\u20138546","journal-title":"Oncogene"},{"issue":"10","key":"1123_CR14","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1073\/pnas.0409773102","volume":"102","author":"JA Engelman","year":"2005","unstructured":"Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C, Cichowski K, Johnson BE, Cantley LC (2005) ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102(10):3788\u20133793","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1123_CR15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00280-004-0867-1","volume":"55","author":"QL Fan","year":"2005","unstructured":"Fan QL, Zou WY, Song LH, Wei W (2005) Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo. Cancer Chemother Pharmacol 55(2):189\u2013196","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1123_CR16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1067\/mtc.2002.119694","volume":"123","author":"S Frese","year":"2002","unstructured":"Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA (2002) Enhancement of Apo2L\/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein. J Thorac Cardiovasc Surg 123(1):168\u2013174","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"1123_CR17","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/156652405774641034","volume":"5","author":"FJ Giles","year":"2005","unstructured":"Giles FJ, Albitar M (2005) Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 5(7):653\u2013661","journal-title":"Curr Mol Med"},{"issue":"7","key":"1123_CR18","first-page":"2609","volume":"118","author":"M Guix","year":"2008","unstructured":"Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Investig 118(7):2609\u20132619","journal-title":"J Clin Investig"},{"issue":"10","key":"1123_CR19","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.1158\/0008-5472.CAN-07-6286","volume":"68","author":"PS Hahnel","year":"2008","unstructured":"Hahnel PS, Thaler S, Antunes E, Huber C, Theobald M, Schuler M (2008) Targeting AKT signaling sensitizes cancer to cellular immunotherapy. Cancer Res 68(10):3899\u20133906","journal-title":"Cancer Res"},{"issue":"5","key":"1123_CR20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10637-007-9060-9","volume":"25","author":"AR Hanauske","year":"2007","unstructured":"Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, Ma D, Chen V, Paoletti P, Niyikiza C (2007) In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Investig New Drugs 25(5):417\u2013423","journal-title":"Investig New Drugs"},{"issue":"3","key":"1123_CR21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","volume":"11","author":"BH Jiang","year":"2008","unstructured":"Jiang BH, Liu LZ (2008) Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 11(3):63\u201376","journal-title":"Drug Resist Updat"},{"key":"1123_CR22","unstructured":"Johnston SR (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(Suppl 1):S28\u2013S36"},{"issue":"Pt 20","key":"1123_CR23","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","volume":"122","author":"M Laplante","year":"2009","unstructured":"Laplante M, Sabatini DM (2009) mTOR signaling at a glance. J Cell Sci 122(Pt 20):3589\u20133594","journal-title":"J Cell Sci"},{"issue":"1\u20132","key":"1123_CR24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","volume":"11","author":"J LoPiccolo","year":"2008","unstructured":"LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA (2008) Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11(1\u20132):32\u201350","journal-title":"Drug Resist Updat"},{"issue":"2","key":"1123_CR25","first-page":"119","volume":"8","author":"JW Neal","year":"2010","unstructured":"Neal JW, Sequist LV (2010) First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clin Adv Hematol Oncol 8(2):119\u2013126","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"1123_CR26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1349-7006.2009.01358.x","volume":"101","author":"H Ozasa","year":"2010","unstructured":"Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R (2010) Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. Cancer Sci 101(1):161\u2013166","journal-title":"Cancer Sci"},{"issue":"8","key":"1123_CR27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1200\/JCO.2007.14.5466","volume":"27","author":"M Reck","year":"2009","unstructured":"Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227\u20131234","journal-title":"J Clin Oncol"},{"issue":"9","key":"1123_CR28","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","volume":"28","author":"L Righi","year":"2010","unstructured":"Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28(9):1534\u20131539","journal-title":"J Clin Oncol"},{"issue":"4","key":"1123_CR29","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1634\/theoncologist.2008-0230","volume":"14","author":"JS Ross","year":"2009","unstructured":"Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4):320\u2013368","journal-title":"Oncologist"},{"issue":"24","key":"1123_CR30","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550","journal-title":"N Engl J Med"},{"issue":"6","key":"1123_CR31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ceb.2005.09.009","volume":"17","author":"DD Sarbassov","year":"2005","unstructured":"Sarbassov DD, Ali SM, Sabatini DM (2005) Growing roles for the mTOR pathway. Curr Opin Cell Biol 17(6):596\u2013603","journal-title":"Curr Opin Cell Biol"},{"issue":"21","key":"1123_CR32","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543\u20133551","journal-title":"J Clin Oncol"},{"issue":"2","key":"1123_CR33","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92\u201398","journal-title":"N Engl J Med"},{"issue":"1","key":"1123_CR34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","volume":"64","author":"W Schuler","year":"1997","unstructured":"Schuler W, Sedrani R, Cottens S, Haberlin B, Schulz M, Schuurman HJ, Zenke G, Zerwes HG, Schreier MH (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 64(1):36\u201342","journal-title":"Transplantation"},{"issue":"6","key":"1123_CR35","first-page":"1116","volume":"57","author":"C Shih","year":"1997","unstructured":"Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM (1997) LY231514, a pyrrolo[2, 3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57(6):1116\u20131123","journal-title":"Cancer Res"},{"issue":"3","key":"1123_CR36","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0006-2952(03)00287-9","volume":"66","author":"J Sigmond","year":"2003","unstructured":"Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ (2003) Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66(3):431\u2013438","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1123_CR37","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/jid.2008.379","volume":"129","author":"T Sinnberg","year":"2009","unstructured":"Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F (2009) Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Investig Dermatol 129(6):1500\u20131515","journal-title":"J Investig Dermatol"},{"issue":"4","key":"1123_CR38","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16(4):525\u2013537","journal-title":"Ann Oncol"},{"issue":"3","key":"1123_CR39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471\u2013484","journal-title":"Cell"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1123-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-011-1123-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-011-1123-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T22:40:05Z","timestamp":1559083205000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-011-1123-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,28]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["1123"],"URL":"https:\/\/doi.org\/10.1007\/s00432-011-1123-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,28]]}}}